Insigneo Advisory Services LLC Sells 1,811 Shares of Abbott Laboratories (NYSE:ABT)

Insigneo Advisory Services LLC lowered its holdings in shares of Abbott Laboratories (NYSE:ABT) by 12.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 12,436 shares of the healthcare product maker’s stock after selling 1,811 shares during the quarter. Insigneo Advisory Services LLC’s holdings in Abbott Laboratories were worth $1,407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Stenger Family Office LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at about $434,000. Evergreen Capital Management LLC grew its stake in shares of Abbott Laboratories by 2.7% in the 4th quarter. Evergreen Capital Management LLC now owns 16,925 shares of the healthcare product maker’s stock valued at $1,914,000 after purchasing an additional 445 shares during the period. Finward Bancorp bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $622,000. Delaney Dennis R boosted its stake in Abbott Laboratories by 1.7% in the 4th quarter. Delaney Dennis R now owns 60,571 shares of the healthcare product maker’s stock valued at $6,851,000 after buying an additional 985 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board grew its position in Abbott Laboratories by 393.4% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 11,742 shares of the healthcare product maker’s stock valued at $1,328,000 after acquiring an additional 9,362 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 2.8 %

NYSE:ABT opened at $129.74 on Thursday. The stock’s fifty day simple moving average is $130.64 and its 200-day simple moving average is $121.60. The firm has a market capitalization of $225.01 billion, a P/E ratio of 16.96, a P/E/G ratio of 2.52 and a beta of 0.80. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. Equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.82%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Wall Street Analysts Forecast Growth

ABT has been the topic of several recent analyst reports. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 23rd. UBS Group raised their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. StockNews.com downgraded Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Citigroup lifted their price objective on Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus increased their target price on Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $137.94.

Insider Buying and Selling

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the sale, the executive vice president now directly owns 125,697 shares in the company, valued at $16,152,064.50. This trade represents a 15.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the transaction, the senior vice president now directly owns 31,970 shares of the company’s stock, valued at approximately $4,417,294.90. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 116,449 shares of company stock valued at $15,463,316. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.